UltraDx Bio is announcing the first round of closing of nearly 100 mm RMB funding from world renowned VCs such as ARCH and GF Hong Kong.
China--Nov 8, 2023, "With full joy and passion, I am announcing that we make a significant step towards our mission to make the world a healthier planet by aligning cutting-edge SIMOA technology from Quanterix, blue ocean markets, and resources and funds, with our first closing of funding. We are committed to working with leading scientists and clinicians to advance the early diagnosis of AD and other neurodegenerative diseases, cancers, cardiovascular, inflammatory, infectious diseases, etc., so as to enable early treatment and intervention.” said Jay Dong, Founder and CEO of UltraDx.
“We are super excited about the diagnostic opportunity using SIMOA for the early diagnosis of AD and other diseases areas in China” Keith Crandell, Managing Partner of ARCH, mentioned.
“We are excited about this technology and its potential, and very impressed by the team led by Jay Dong for his passion, energy and leadership. GF Hong Kong is in full support of companies that could bring a solution to this large unmet need market and hope that patients will soon benefit from this technology. “
“We are excited about the potential of Quanterix SIMOA technology and happy to make it available in the clinical market in China. We are announcing our licensing partnerships with Quanterix to accelerate SIMOA clinical application in China. With the strong support of leading VCs such as ARCH and GF HK, and a vast emerging market, we are confident that we will be making a significant contribution to the early diagnosis of Alzheimer’s disease, and other diseases, so to enable early treatment and to help patients and their families, and to make the world a healthier planet” , said Jay Dong.
Masoud Toloue, CEO of Quanterix, added “We believe early detection is an important starting point for the treatment of disease. Many Alzheimer’s blood biomarkers are undetectable or cannot be detected early enough without SIMOA’s ultrasensitive technology. Our IVD partnership with UltraDx will accelerate access and improve early diagnosis of Alzheimer’s disease for patients in China."
